Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 11, 2019British Journal of Clinical PharmacologyOpen Access

Therapeutic concentration achievement and allograft survival comparing usage of conventional tacrolimus doses and CYP3A5 genotype‐guided doses in renal transplantation patients

View Full Paper
Ask AI
Bookmark
Share

Authors

SASirirat AnutrakulchaiKhon Kaen UniversityCPCholatip PongskulKhon Kaen UniversityKKKittrawee KritmetapakKhon Kaen University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Anutrakulchai et al. (2019) studied this question.

synapsesocial.com/papers/6a623ea70579a17fd4c94d21https://doi.org/10.1111/bcp.13980
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing2010 · 364 citations
  2. 2The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients2004 · 446 citations
  3. 3Influence of CYP3A5 and MDR1 (ABCB1) Polymorphisms on the Pharmacokinetics of Tacrolimus in Renal Transplant Recipients2004 · 251 citations
  4. 4Contribution of CYP3A5 to the in Vitro Hepatic Clearance of Tacrolimus2005 · 220 citations